Streptococcal toxic shock syndrome or Kawasaki disease? Two case studies of children with group A streptococcal pneumonia empyema;Syndrome de choc toxinique streptococcique ou syndrome de Kawasaki? À propos de 2 cas cliniques d'enfants présentant une pleuropneumopathie à streptocoque bêta hémolytique du groupe A

Archives de Pediatrie

Volumn 18, Issue 12, 2011, Pages 1305-1309

  Bosland, A ^a   Arlaud, K ^a   Rousset Rouviere C ^a   Fouilloux, V ^a   Paut, O ^a   Dubus, J C ^a,b   Bosdure, E ^a  

^a TIMONE HOSPITAL   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; IMMUNOGLOBULIN;

ARTICLE; CASE REPORT; CHILD; CLINICAL FEATURE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; EMPYEMA; GROUP A STREPTOCOCCAL INFECTION; HUMAN; IMMUNOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOPHYSIOLOGY; STREPTOCOCCUS PNEUMONIA; TOXIC SHOCK SYNDROME; TREATMENT PLANNING;

EID: 82955248041     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/j.arcped.2011.09.027     Document Type: Article

References (15)

1. Cone L.A., Woodard D.R., Schlievert P.M., et al. Clinical and bacteriological observations of a toxic shock-like syndrom due to Streptococcus pyogenes. N Eng J Med 1987, 317:146-149.
2. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Jpn J Allergy 1967, 16:178-222.
3. Centers for disease control prevention (the working group on severe streptococcal infection). Defining the group A streptococcal toxic shock syndrome: rational and consensus definitions. JAMA 1993, 269(3):390-391.
4. Groupe de travail sur les infections invasives à streptocoque du groupe A. Infections invasives à streptocoques du groupe A: situations, orientations et recommandations. Québec 2e édition 2007 ; (site consulté en juillet 2010). http://www.santepubmtl.qc.ca/Mi/prevention/infection/pdf/GuideInfectionsInvasivesstrept.pdf.
5. The Japan Kawasaki Disease Research Center. Diagnostic guidelines of Kawasaki disease. MCLS. The 5th revised edition. February 2002.
6. Bisno A., Brito M., Collins C. Molecular basis of group A streptococcal virulence. Lancet Infect Dis 2003, 3:191-200.
7. Brown E.J. The molecular basis of streptococcal toxic shock syndrome. N Engl J Med 2004, 13(350):20.
8. Suenaga T., Suzuki H., Shibuta S., et al. Detection of multiple superantigen genes in stools of patients with Kawasaki disease. J Pediatr 2009, 155:266-270.
9. Matsubara K., Fukaya T., Miwa K., et al. Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogene in Kawasaki disease. Clin Exp Immunol 2006, 143:427-434.
10. Gaudelus J., Dubos F., Dommergues M., et al. Antibiothérapie des pleuropneumopathies de l'enfant: quelles leçons tirer des études cliniques publiées et propositions thérapeutiques. Arch Pediatr 2008, 15:584-592.
11. Darenberg J., Ihendyane N., Sjolin J., et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double blind, placebo-controlled trial. Clin Infect Dis 2003, 37:333-340.
12. Kaul R., McGeer A., Norrby-Teglund A., et al. Intravenous immunoglobulin for therapy of streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 1999, 28:800-807.
13. Committee on infectious diseases, American academy of pediatrics. Toxic shock syndrome. In: The Red Book. 27th ed. Elk Grove Village, IL: Committee on infectious diseases, American academy of pediatrics, 2006:660-64.
14. Shah S.S., Hall M., Srivastava R., et al. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis 2009, 49:1369-1376.
15. Valiquette L., Low D., McGeer A. Assessing the impact of intravenous immunoglobulin in the management of streptococcal toxic shock syndrome: a noble but difficult quest. Clin Infect Dis 2009, 49:1377-1379.